Literature DB >> 24601047

Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.

M Bozkurt1, A E Yumru2, I Aral3.   

Abstract

PURPOSE: The aim of this study was to investigate the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPPV) of the serum levels of CA-125, CA15-3, CA19-9, carcinoembryonic antigen (CEA), and alpha-fetoprotein (AFP) in the differentiation of benign and malignant ovarian tumors histopathologically diagnosed in patients and to determine the effects of the different test combinations on diagnostic accuracy.
MATERIAL AND METHODS: One-hundred sixty-eight patients that had their preoperative CA-125, CA15-3, CA19-9, CEA, AFP levels assessed and that were subsequently surgically treated for adnexal masses, were included in the study. For each tumor markers in these patients with histopathologically-confirmed diagnosis, the sensitivity, specificity, PPV and NPV, and diagnostic accuracy, and odds ratio were calculated.
RESULTS: The sensitivity, specificity, PPV, NPV of CA125 with cut-off 35 U/ml, were found to be 78.9%, 86.9%, 63.8%, and 93.3%, respectively. The diagnostic odds ratio of CA-125 with cut-off of 35 U/ml, was found to be 25. With cut-off65 U/ml, the sensitivity, specificity, PPV, NPV values were 65.7%, 95.3%, 80.6%, and 90.5%, respectively. The sensitivity, specificity, PPV, and NPV of CEA were 16%, 93%, 37%, and 83%, respectively. For AFP, the sensitivity, specificity, PPV and NPV were to be 2.6%, 98%, 33.3%, and 77.5%, respectively. For CA 15-3, the sensitivity, specificity, PPV and NPV were found to be 26.3% 96.1%, 66.6%, and 81.6%, respectively. Likelihood ratio tests: positive (LR+) = 6.83 and negative (LR-) = 0.76, with an odds ratio: 8.9. The risk of malignancy for adnexal masses with higher CA15-3 increased by approximately nine times. For CA19-9, the sensitivity, specificity, PPV and NPV value were found to be 18.4%, 93%, 43.7%, and 79.6%, respectively. CA19-9 was not statistically significant in the differentiation of benign and malignant of adnexal masses. Even the combinations of CA125 + CEA + CA19-9 and CA125 + CEA + CA19-9 +AFP and CA125 + CA15-3 made a small contribution (one, two, and four cases, respectively), but was not statistically significant.
CONCLUSION: The levels of CA-125 and CA15-3 were found to be significant in order to distinguish benign and malign; CA 19-9, CEA, and AFP were not found to be significant. The different test combinations did not have contribution for diagnostic accuracy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24601047

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  9 in total

1.  Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors.

Authors:  Rafał Watrowski; Georg Heinze; Christoph Jäger; Johannes Forster; Robert Zeillinger
Journal:  Tumour Biol       Date:  2016-05-20

2.  Multivariate Analysis of Prognostic Biomarkers in Surgically Treated Endometrial Cancer.

Authors:  Jianpei Li; Jianhua Lin; Yaoling Luo; Miaohuan Kuang; Yijun Liu
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

3.  Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses.

Authors:  Wan Kyu Eo; Ki Hyung Kim; Eun Joo Park; Heung Yeol Kim; Hong-Bae Kim; Suk Bong Koh; Jeong Namkung
Journal:  J Cancer       Date:  2018-03-08       Impact factor: 4.207

Review 4.  Carbohydrate antigen 19-9 - tumor marker: Past, present, and future.

Authors:  Tsinrong Lee; Thomas Zheng Jie Teng; Vishal G Shelat
Journal:  World J Gastrointest Surg       Date:  2020-12-27

5.  Leveraging deep phenotyping from health check-up cohort with 10,000 Korean individuals for phenome-wide association study of 136 traits.

Authors:  Eun Kyung Choe; Manu Shivakumar; Anurag Verma; Shefali Setia Verma; Seung Ho Choi; Joo Sung Kim; Dokyoon Kim
Journal:  Sci Rep       Date:  2022-02-04       Impact factor: 4.379

6.  Comparison of Ultrasound and Tumor Marker CA125 in Diagnosis of Adnexal Mass Malignancies.

Authors:  Fariba Behnamfar; Fatemeh Esmaeilian; Atoosa Adibi; Safoura Rouholamin
Journal:  Adv Biomed Res       Date:  2022-02-28

Review 7.  Evaluation of the potential of ultrasound-mediated drug delivery for the treatment of ovarian cancer through preclinical studies.

Authors:  Yi-Chao Wang; Jing-Yan Tian; Ying-Ying Han; Yun-Fei Liu; Si-Yao Chen; Feng-Jun Guo
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

Review 8.  ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.

Authors:  Dirk Timmerman; François Planchamp; Tom Bourne; Chiara Landolfo; Andreas du Bois; Luis Chiva; David Cibula; Nicole Concin; Daniela Fischerova; Wouter Froyman; Guillermo Gallardo Madueño; Birthe Lemley; Annika Loft; Liliana Mereu; Philippe Morice; Denis Querleu; Antonia Carla Testa; Ignace Vergote; Vincent Vandecaveye; Giovanni Scambia; Christina Fotopoulou
Journal:  Int J Gynecol Cancer       Date:  2021-06-10       Impact factor: 3.437

9.  Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors.

Authors:  Arb-Aroon Lertkhachonsuk; Supree Buranawongtrakoon; Navamol Lekskul; Naparat Rermluk; Wei-Wei Wee-Stekly; Chuenkamon Charakorn
Journal:  J Obstet Gynaecol Res       Date:  2020-08-23       Impact factor: 1.730

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.